News

As per the agreement, Minophagen will have the exclusive rights to develop and commercialize the drug candidate. Eisai holds the right of first negotiation for the commercialization of

The recall was issued because cracks can form in the heel (bottom) and sides of some vials of 1662, 1679, and 1683 lots. The cracks may lead to

The payment was triggered by the approval of an investigational new drug (IND) application from the FDA for the Phase I trial for a Nanobody. Both the companies

Airborne develops and sells immune support products including iconic effervescent tablets, new chewable tablets and on-the-go packets, all in a variety of flavors. The all-cash transaction is done

MusclePharm CEO Brad Pyatt said Canada is a core market for Fitness as well as the Mecca for Ultimate Fighting Championship (UFC). "In the next 36 months, we

Kiklin capsules, amine-functional polymers, bind to phosphate in the gastrointestinal tract and decrease the serum phosphorus concentration, there by inhibiting absorption of phosphate into the human body. Phase

The SHINE, BRIGHT and ENLIGHTEN studies, part of IGNITE Phase III trial program intended to form the basis for an NDA filing in COPD, met their primary endpoints.

Cephalon, a wholly owned subsidiary of Teva Pharmaceutical Industries, will market the product. Provigil will continue to be manufactured under the brand product’s NDA at the same facility

The Phase III investigational study did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a two-year treatment period. The SPD476, MMX mesalamine